FindTrial
Sign In

Effect of rivaroxaban on preventing deep-vein thrombosis in aged diabetics with femoral neck fractures after hip replacement

Effect of rivaroxaban on preventing deep-vein thrombosis in aged diabetics with femoral neck fractures after hip replacement

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-17011510
Enrollment
Unknown
Registered
2017-05-27
Start date
2011-02-01
Completion date
Unknown
Last updated
2017-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep-vein thrombosis in aged diabetics with femoral neck fractures after hip replacement

Interventions

Rivaroxaban group:rivaroxaban
Control group:Non rivaroxaban

Sponsors

Weifang People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients whose weight is between 40 and 100 kg and aged more than 40 years; diabetic patients with femoral neck fractures; patients need hip replacement as a result of femoral neck fractures; patients diagnosed with negative DVT in lower limbs by preoperative color duplex Doppler ultrasound (CDDU); patients approved the medication regimen.

Exclusion criteria

Exclusion criteria: With a history of DVT; those with prothrombin activity lower than 60% or platelet content lower than 100 × 10^9/L or higher than 300 × 10^9/L; patients diagnosed with positive DVT in lower limbs by preoperative CDDU or had lower limb varicose.

Design outcomes

Primary

MeasureTime frame
TEG;hemoglobin;platelet;prothrombin time;activated partial thromboplastin time;—

Countries

China

Contacts

Public ContactYimin Zhang

Department of Joint Surgery, Weifang People's Hospital

yimin_ZYZ@163.com+86 13070718318

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026